Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH mainly act as vasodilating agents. Since excessi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales-Cano, Daniel, Izquierdo-García, Jose Luis, Barreira, Bianca, Esquivel-Ruiz, Sergio, Callejo, Maria, Pandolfi, Rachele, Villa-Valverde, Palmira, Rodríguez, Ignacio, Cogolludo, Angel, Ruiz-Cabello, Jesus, Perez-Vizcaino, Francisco, Moreno, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090662/
https://www.ncbi.nlm.nih.gov/pubmed/37063275
http://dx.doi.org/10.3389/fphar.2023.1021535

Ejemplares similares

Ejemplares similares